LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
MEDIPOST gets patent in US
MEDIPOST conducts the first procedure using the stem cell agent, CARTISTEM.
Mechanism of treatment for cartilage regeneration using stem cells, the first in the world
‘NEUROSTEM-AD’ the treatment for Alzheimer’s disease requested for phase 1.2a clinical trials
MEDIPOST publishes stem cell research
MEDIPOST paves way for ‘stem cell era’
Consecutive international patents in dementia treatment
‘CARTISTEM’, intensive report on Chicago’s WGN-TV
Stem cell dementia treatment 2a clinically approved
Core technology of the Alzheimer’s dementia treatment patented in US
Lung Treatment Medicine ‘PNEUMOSTEM’ designated Orphan Drug by US FDA
Strengthening marketing of ‘CARTISTEM’ by participating in numerous overseas academic conferences
1
2
3
4
…
10
Next
Menu
